JP2024515165A5 - - Google Patents

Info

Publication number
JP2024515165A5
JP2024515165A5 JP2023558946A JP2023558946A JP2024515165A5 JP 2024515165 A5 JP2024515165 A5 JP 2024515165A5 JP 2023558946 A JP2023558946 A JP 2023558946A JP 2023558946 A JP2023558946 A JP 2023558946A JP 2024515165 A5 JP2024515165 A5 JP 2024515165A5
Authority
JP
Japan
Prior art keywords
cdr
cancer
antigen
binding fragment
sequence numbers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515165A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/021945 external-priority patent/WO2022204514A1/en
Publication of JP2024515165A publication Critical patent/JP2024515165A/ja
Publication of JP2024515165A5 publication Critical patent/JP2024515165A5/ja
Pending legal-status Critical Current

Links

JP2023558946A 2021-03-26 2022-03-25 抗klrg1抗体 Pending JP2024515165A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166663P 2021-03-26 2021-03-26
US63/166,663 2021-03-26
US202163294436P 2021-12-29 2021-12-29
US63/294,436 2021-12-29
PCT/US2022/021945 WO2022204514A1 (en) 2021-03-26 2022-03-25 Anti-klrg1 antibodies

Publications (2)

Publication Number Publication Date
JP2024515165A JP2024515165A (ja) 2024-04-05
JP2024515165A5 true JP2024515165A5 (cg-RX-API-DMAC7.html) 2025-04-15

Family

ID=81385062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558946A Pending JP2024515165A (ja) 2021-03-26 2022-03-25 抗klrg1抗体

Country Status (10)

Country Link
US (1) US20240174754A1 (cg-RX-API-DMAC7.html)
EP (1) EP4314066A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515165A (cg-RX-API-DMAC7.html)
KR (1) KR20230162798A (cg-RX-API-DMAC7.html)
AU (1) AU2022246164A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023019512A2 (cg-RX-API-DMAC7.html)
CA (1) CA3212311A1 (cg-RX-API-DMAC7.html)
IL (1) IL307241A (cg-RX-API-DMAC7.html)
MX (1) MX2023011102A (cg-RX-API-DMAC7.html)
WO (1) WO2022204514A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3852779A4 (en) 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4609546A (en) 1982-06-24 1986-09-02 Japan Chemical Research Co., Ltd. Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
CA3026182A1 (en) * 2016-06-03 2017-12-07 Steven Greenberg Klrg1 signaling therapy
US20210002373A1 (en) * 2018-03-01 2021-01-07 Nextcure, Inc. KLRG1 Binding Compositions and Methods of Use Thereof
EP3852779A4 (en) * 2018-09-17 2022-06-08 Abcuro, Inc. ANTI-KLRG1 ANTIBODIES
MX2021012171A (es) * 2019-04-09 2021-12-10 Abcuro Inc Anticuerpos reductores del miembro 1 de la subfamilia g de receptores similares a la lectina de linfocitos citoliticos (klrg1).

Similar Documents

Publication Publication Date Title
JP2021534096A5 (cg-RX-API-DMAC7.html)
AU2013327116B2 (en) Combination of anti-KIR antibodies and anti-PD-1 antibodies to treat cancer
JP2022101693A5 (cg-RX-API-DMAC7.html)
JP2023528036A5 (cg-RX-API-DMAC7.html)
JP2020501531A5 (cg-RX-API-DMAC7.html)
JP2015509947A5 (cg-RX-API-DMAC7.html)
JP2017507900A5 (cg-RX-API-DMAC7.html)
JP2018070648A5 (cg-RX-API-DMAC7.html)
JP2020502271A5 (cg-RX-API-DMAC7.html)
JP2024527606A5 (cg-RX-API-DMAC7.html)
JP2016510002A5 (cg-RX-API-DMAC7.html)
JP2014158469A5 (cg-RX-API-DMAC7.html)
JP2017500057A5 (cg-RX-API-DMAC7.html)
JP2018500014A5 (cg-RX-API-DMAC7.html)
JP2022528030A5 (cg-RX-API-DMAC7.html)
JP2024532886A5 (cg-RX-API-DMAC7.html)
JP2022528721A5 (cg-RX-API-DMAC7.html)
JP2024541680A5 (cg-RX-API-DMAC7.html)
JP2022512642A5 (cg-RX-API-DMAC7.html)
JP2023549316A5 (cg-RX-API-DMAC7.html)
JP2020522488A5 (cg-RX-API-DMAC7.html)
JP2022553851A5 (cg-RX-API-DMAC7.html)
JP2021531255A5 (cg-RX-API-DMAC7.html)
JP2025508867A5 (cg-RX-API-DMAC7.html)
JP2023510429A5 (cg-RX-API-DMAC7.html)